secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001193125-23-001236
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Acumen appoints Dr. Derrell Porter to board effective Jan. 4, 2023
------------------------------------------------------------------

- Dr. Porter appointed as Class II independent director; named to Nominating and Governance Committee.
- He receives 50,000-share stock option with 10-yr term, vesting monthly over 3 years.
- Annual retainer of $35,000 for board service and $4,000 for committee service.
- Dr. Porter is Founder/CEO of Cellevolve; brings drug development and commercialization expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523001236/0001193125-23-001236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523001236/d367027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-001236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer